Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 4/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869147 | 0.95 | METAP2 (0.36) | HTR2CSLC6A4RXRARXRBRXRG | |
| SCHEMBL30869028 | 0.87 | HTR2C (0.35) | HTR2CSLC6A4RXRARXRBRXRG | |
| SCHEMBL30869059 | 0.86 | ATR (0.40) | RXRARXRBRXRGATRKRAS | |
| SCHEMBL27376514 | 0.84 | ATR (0.42) | RXRARXRBRXRGATR | |
| SCHEMBL30797851 | 0.82 | ATR (0.43) | RXRARXRBRXRGATR | |
| SCHEMBL30869008 | 0.79 | ATR (0.39) | RXRARXRBRXRGATRKRAS | |
| SCHEMBL30869053 | 0.79 | ATR (0.34) | RXRARXRBRXRGATR | |
| SCHEMBL30869155 | 0.79 | RXRA (0.37) | RXRARXRBRXRG | |
| SCHEMBL30869134 | 0.79 | ATR (0.37) | RXRARXRBRXRGATRKRAS | |
| SCHEMBL32690920 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |